Drug absorption modeling as a tool to define the strategy in clinical formulation development

AAPS Journal

Volumn 10, Issue 3, 2008, Pages 473-479

  Kuentz, Martin ^a  

^a UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

Clinical; Design space; Drug absorption; Formulation; Parameter sensitivity; Physiologically based modelling

Indexed keywords

GLIBENCLAMIDE; LAB 687; MACROGOL; MEFENAMIC ACID; NEW DRUG; POLYSORBATE 80; R 1315; UNCLASSIFIED DRUG;

ACCURACY; AREA UNDER THE CURVE; COMPUTER MODEL; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG FORMULATION; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; POWDER; PREDICTION; SENSITIVITY ANALYSIS; SHORT SURVEY;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; BIOPHARMACEUTICS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL;

EID: 57149095631     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9054-3     Document Type: Short Survey

References (45)

1. P. Cuatrecasas. Drug discovery in jeopardy. J. Clin. Invest. 116(11):2837-2842 (2006).
2. I. Kola, and J. Landis. Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discov. 3(8):711-715 (2004).
3. J. Wang, and L. Urban. The impact of early ADME profiling on drug discovery and development strategy. Drug Discov. 4:73-86 (2004).
4. H. Van de Waterbeemd, and E. Gifford. ADMET in silico modeling: Towards prediction paradise? Nat. Rev. 2(3):192-204 (2003).
5. F. Lombardo, E. Gifford, and M. Y. Shalaeva. In silico ADME prediction: Data, models, facts, myths. Minirev Med. Chem. 3(8):861-875 (2003).
6. C. A. Lipinski, F. Lombardo B. W. Dominy et al. Experimental and computational approaches to Estimate solubiliy and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23(1-3):3-25 (1997).
7. C. W. Andrews, L. Bennett, and L. X. Yu. Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship. Pharm. Res. 17(6):639-44 (2000).
8. F. Yoshida, and J. G. Topliss. QSAR model for drug human oral bioavailability. J. Med. Chem. 43(13):2575-2585 (2000).
9. D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward, and K. D. Kopple. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45:2615-2623 (2002).
10. M. A. C. Perez, M. B. Sanz, L. R. Torres, R. G. Avalos, and M. P. Gonzalez. Diaz HGA topological sub-structural approach for predicting human intestinal absorption of drugs. Eur. J. Med. Chem. 39(11):905-916 (2004).
11. E. Deconinck, Q. S. Xu, R. Put, D. Coomans, D. L. Massart, and Y. Vander Heyden. Prediction of gastro-intestinal absorption using multivariate adaptive regression splines. J. Pharm. Biomed Anal. 39(5):1021-1030 (2005).
12. E. Deconinck, H. Ates, N. Callebaut, E. Van Gyseghem, and Y. Vander Heyden. Evaluation of chromatographic descriptors for the prediction of gastro-intestinal absorption of drugs. J. Chromatogr., A. 1138(1-2):190-202 (2007).
13. T. Hou, J. Wang, W. Zhang, and X. Xu. ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J. Chem. Inf. Model. 47(1):208-218 (2007).
14. T. Hou, J. Wang, and Y. Li. ADME evaluation in drug discovery. 8. The prediction of human intestinal absorption by a support vector machine. J. Chem. Inf. Model. 47(6):2408-2415 (2007).
15. T. Hou, J. Wang, W. Zhang, and X. Xu. ADME evaluation in drug discovery. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules? J. Chem. Inf. Model. 47(2):460-463 (2007).
16. J. Dressman, G. Amidon, and D. Fleisher. Absorption potential: Estimation of the fraction absorbed for orally administered compounds. J. Pharm. Sci. 74(5):588-589 (1985).
17. K. Johnson, and A. Swindell. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. 13(12):1795-1798 (1996).
18. L. Yu, J. Crison, and G. Amidon. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int. J. Pharm. 171(2):157-163 (1996).
19. L. Yu, and G. Amidon. Characterisation of small intestinal transit time distribution in humans. Int. J. Pharm. 171(2):157-163 (1998).
20. L. Yu, and G. Amidon. Saturable small intestinal drug absorption in humans: Modeling and interpretation of cefatrizine data. Eur. J. Pharm. Biopharm. 45(2):199-203 (1998).
21. B. Agoram, W. Woltosz, and M. Bolger. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50(S1):S41-67 (2001).
22. P. Ni, N. Ho, J. Fox, H. Leuenberger, and W. Higuchi. Theoretical model studies of intestinal drug absorption V. Non-steady-state fluid flow and absorption. Int. J. Pharm. 5(1):33-47 (1980).
23. N. Ho, J. Park, P. Ni, and W. Higuchi. Advancing quantitative and mechanistic approaches in interfacing gastrointestinal drug absorption studies in animals and humans. In W. Crouthamel and A. Sarapu (eds.), Animal Models for Oral Drug Delivery. In Situ and In Vivo Approaches, American Pharmaceutical Association, Washington, 1983, pp. 27-106.
24. S. Willmann, W. Schmitt, J. Keldenich, and J. Dressman. A physiological model for simulating gastrointestinal flow and drug absorption in rats. Pharm. Res. 20(11):1766-1771 (2003).
25. S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J. Dressman. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47(16):4022-4031 (2004).
26. S. Willmann, A. N. Ediginton, and J. Dressman. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm. Res. 24(7):1275-1282 (2007).
27. G. M. Grass. Simulation models to predict oral drug absorption from in vitro data. Adv. Drug Deliv. Rev. 23:199-219 (1997).
28. D. A. Norris, G. D. Leesman, P. J. Sinko, and G. M. Grass. Development of predictive pharmacokinetic simulation models for drug discovery. J. Controlled Release. 65:55-62 (2000).
29. N. Parrott, and Th. Lavé. Prediction of intestinal absorption: comparative assessment of GastroPlusä and IDEAä. Euro. J. Pharm. Sci. 17:51-61 (2002).
30. A. Kalampokis, P. Argyrakis, and P. Macheras. Heterogenous tube model for the study of small intestinal transit flow. Pharm. Res. 16(1):87-91 (1999).
31. A. Kalampokis, P. Argyrakis, and P. Macheras. A heterogenous tube model of intestinal drug absorption based on probabilistic concepts. Pharm. Res. 16(11):1764-1769 (1999).
32. N. Parrott, H. Jones, N. Paquereau, and T. Lavé. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic & Clin. Pharmacol. Toxicol. 96:193-199 (2005).
33. M. Kuentz, S. Nick, N. Parrott, and D. Roethlisberger. A strategy for preclinical formulation development using GastroPlusä as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur. J. Pharm. Sci. 27(1):91-99 (2006).
34. G. Amidon, H. Lennernas, V. Shah, and J. Crison. A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3):413-420 (1995).
35. E. Galia, E. Nicolaides, D. Hörter, R. Löbenberg, Ch. Reppas, and J. Dressman. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15(5):698-705 (1998).
36. M. Vertzoni, N. Fotaki, E. Kostewicz, E. Stippler, Ch. Leuner, E. Nicolaides, J. Dressman, and Ch. Reppas. Dissolution media simulation the intralumenal composition of the small intestinal intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 56:453-562 (2004).
37. R. M. Dannenfelser, H. He, Y. Joshi, S. Bateman, and A. Serajuddin. Development of clinical dosage forms for a poorly water soluble drug I: application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J. of Pharm. Sci. 93(5):1165-1175 (2004).
38. M. Tubic, D. Wagner, H. Spahn-Langguth, M. Bolger, and P. Langguth. In silico Modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm. Res. 23(8):1712-1720 (2006).
39. H. Wei, and R. Löbenberg. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Euro. J. Pharm. Sci. 29:45-52 (2006).
40. A. Aburub, D. S. Risley, and D. Mishra. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe. Int. J. Pharm. 347:16-22 (2008).
41. J. Dressman, G. Amidon, C. Reppas, and V. Shah. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm. Res. 15:11-22 (1998).
42. G. A. Lewis, D. Mathieu, and R. Phan-Tan-Luu. Pharmaceutical Experimental Design. Marcel Dekker, New York, 1999, pp 27-184.
43. M. Kuentz, D. Röthlisberger, and W. Richter. Design of experiment (DoE) methods maximize information from a minimal number of animals in special cases of preclinical bioavailability testing. Pharm. Dev. Technol. 8(4):453-458 (2003).
44. C. Dollery. Mefenamic Acid. In Therapeutic Drugs. 2nd edn. Churchill Livingston, Edinburg, London, 1998, pp M21-M24.
45. D. Hummel, and St. Buchmann. Influence of the particle size of mefenamic acid on dissolution and bioavailability of tablets (article in German). Pharm. Ind. 62(6):452-456 (2000).